Clinical Trials in New York

Showing 4961-4980 of 22,668 trials

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

NCT06848231

This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.

Multiple System Atrophy

Yoda Therapeutics Inc.75 participantsStarted Mar 2025

Los Angeles, California, United States • Boston, Massachusetts, United States • Rochester, Minnesota, United States +6 more locations

Active Not RecruitingPhase 2< 1 mile

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

NCT04857034

The purpose of this study is to assess the safety, efficacy, and tolerability of deucravacitinib (BMS-986165) compared with placebo in participants with active discoid and/or subacute cutaneous lupus erythematosus (DLE/SCLE). This study will also assess if deucravacitinib is biologically active and potentially effective in the treatment of participants with moderate to severe DLE/SCLE with or without systemic lupus erythematosus (SLE) that is not well controlled with standard of care therapy.

Lupus Erythematosus, DiscoidLupus Erythematosus, Subacute Cutaneous

Bristol-Myers Squibb74 participantsStarted Jul 2021

Scottsdale, Arizona, United States • Irvine, California, United States • Los Angeles, California, United States +38 more locations

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Find Trials by Condition in New York

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning

Transcranial Magnetic Stimulation in Misophonia

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

OCS DCD Heart + CAP Continued Follow-Up

Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)